David Chang (Jeff Rumans for Endpoints News)

Al­lo­gene, Over­land plot speedy Asia play for off-the-shelf CAR-T with $117M joint ven­ture

David Chang got a good look at what it takes to bring CAR-T ther­a­py to Chi­na and Asia mar­kets when he and Arie Bellde­grun struck a deal with Fo­s­un Phar­ma to form a joint ven­ture around its pi­o­neer­ing lym­phoma treat­ment — which would come to be known as Yescar­ta — in 2017, just af­ter sub­mit­ting a BLA to the FDA.

With Al­lo­gene, the duo’s high pro­file start­up aimed at de­liv­er­ing off-the-shelf CAR-T, he’s do­ing the same.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.